KK2269 is a tumor-targeted bispecific CD40 agonist antibody that activates antigen-presenting cells (APCs) selectively in the presence of EpCAM-positive tumors by binding CD40 on APCs and EpCAM on tumor cells. It is designed to localize immune stimulation to the tumor microenvironment rather than broadly activating CD40 systemically. In preclinical combination studies, KK2269 showed significant antitumor activity with anti-PD-1 antibody, docetaxel, doxorubicin, and oxaliplatin, while gemcitabine did not produce significant activity. The strongest effect was reported with docetaxel, highlighting a chemotherapy-immunotherapy synergy in EpCAM-positive tumor settings. A 2026 Cancer Science study (PMID:41989931) specifically examined docetaxel-induced immune activation and its synergy with KK2269. Overall, KK2269 represents a targeted immuno-oncology approach for EpCAM-expressing cancers through CD40-mediated APC activation.
Cancer
- KK2269 is a tumor-targeted cd40 agonist that activates APCs only in the context of epcam-positive tumors, supporting localized immune stimulation. (PMID:41989931)
- In a 2026 Cancer Science study, KK2269 showed significant antitumor synergy with anti programmed cell death 1 antibody in combination treatment. (PMID:41989931)
- KK2269 combined with docetaxel produced the most significant antitumor effect among the tested regimens. (PMID:41989931)
- Significant antitumor activity was also observed with doxorubicin and oxaliplatin, indicating broad compatibility with multiple cytotoxic backbones. (PMID:41989931)
- gemcitabine did not show significant antitumor activity with KK2269, suggesting regimen-specific synergy rather than a universal chemotherapy effect. (PMID:41989931)